BLACK DIAMOND THERAPEUTICS, INC. Net Income
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Net Income of -$9.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$9.90M.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$9.04M, a 115.98% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $22.33B.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$8.50M.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$82.44M.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$91.17M.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2021 was -$125.60M.
- BLACK DIAMOND THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2020 was -$67.25M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$9.90M 10-Q · filed 2026-08-05 | -$18.94M 10-Q · filed 2026-08-05 | $22.31B derived: sum of 3 quarters · filed 2026-08-05 | $22.30B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$9.04M 10-Q · filed 2026-08-05 | $22.32B derived: sum of 2 quarters · filed 2026-08-05 | $22.31B derived: sum of 3 quarters · filed 2026-08-05 | $22.30B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $22.33B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | $22.32B derived: sum of 2 quarters · filed 2026-04-29 | $22.31B derived: sum of 3 quarters · filed 2026-08-05 | $22.37B DEF 14A · filed 2026-04-29 | $22.37M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$8.50M 10-Q · filed 2025-11-06 | -$19.06M derived: sum of 2 quarters · filed 2026-08-05 | $37.48M 10-Q · filed 2025-11-06 | -$69.58B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$10.56M 10-Q · filed 2026-08-05 | $45.98M 10-Q · filed 2026-08-05 | -$69.58B derived: sum of 3 quarters · filed 2026-08-05 | -$69.59B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $56.54M 10-Q · filed 2026-08-05 | -$69.57B derived: sum of 2 quarters · filed 2026-08-05 | -$69.58B derived: sum of 3 quarters · filed 2026-08-05 | -$69.60B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2024-12-31 | -$69.62B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$69.64B derived: sum of 2 quarters · filed 2026-04-29 | -$69.66B derived: sum of 3 quarters · filed 2026-04-29 | -$69.68B DEF 14A · filed 2026-04-29 | -$69.68M 10-K · filed 2025-03-06 |
| 2024-09-30 | -$15.56M 10-Q · filed 2025-11-06 | -$35.47M derived: sum of 2 quarters · filed 2025-11-06 | -$53.69M 10-Q · filed 2025-11-06 | -$73.10M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$19.91M 10-Q · filed 2025-11-06 | -$38.13M 10-Q · filed 2025-08-07 | -$57.54M derived: sum of 3 quarters · filed 2025-11-06 | -$80.55M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-03-31 | -$18.23M 10-Q · filed 2025-11-06 | -$37.63M derived: sum of 2 quarters · filed 2025-11-06 | -$60.64M derived: sum of 3 quarters · filed 2025-11-06 | -$79.79M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2023-12-31 | -$19.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$42.41M derived: sum of 2 quarters · filed 2025-03-06 | -$61.57M derived: sum of 3 quarters · filed 2025-03-06 | -$82.44M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$23.01M 10-Q · filed 2024-11-05 | -$42.16M derived: sum of 2 quarters · filed 2024-11-05 | -$63.03M 10-Q · filed 2024-11-05 | -$84.11M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$19.15M 10-Q · filed 2024-11-05 | -$40.03M 10-Q · filed 2024-08-06 | -$61.10M derived: sum of 3 quarters · filed 2024-11-05 | -$82.76M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-03-31 | -$20.88M 10-Q · filed 2024-11-05 | -$41.95M derived: sum of 2 quarters · filed 2024-11-05 | -$63.61M derived: sum of 3 quarters · filed 2024-11-05 | -$86.54M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2022-12-31 | -$21.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$42.73M derived: sum of 2 quarters · filed 2024-03-12 | -$65.66M derived: sum of 3 quarters · filed 2024-03-12 | -$91.17M 10-K · filed 2024-03-12 | |
| 2022-09-30 | -$21.65M 10-Q · filed 2023-11-06 | -$44.58M derived: sum of 2 quarters · filed 2023-11-06 | -$70.09M 10-Q · filed 2023-11-06 | -$95.96M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$22.93M 10-Q · filed 2023-11-06 | -$48.44M 10-Q · filed 2023-08-11 | -$74.30M derived: sum of 3 quarters · filed 2023-11-06 | -$109.38M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-03-31 | -$25.51M 10-Q · filed 2023-11-06 | -$51.37M derived: sum of 2 quarters · filed 2023-11-06 | -$86.45M derived: sum of 3 quarters · filed 2023-11-06 | -$120.80M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2021-12-31 | -$25.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$60.94M derived: sum of 2 quarters · filed 2023-03-09 | -$95.30M derived: sum of 3 quarters · filed 2023-03-09 | -$125.60M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$35.08M 10-Q · filed 2022-11-08 | -$69.43M derived: sum of 2 quarters · filed 2022-11-08 | -$99.73M 10-Q · filed 2022-11-08 | -$122.36M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$34.35M 10-Q · filed 2022-11-08 | -$64.65M 10-Q · filed 2022-08-09 | -$87.28M derived: sum of 3 quarters · filed 2022-11-08 | -$105.19M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-03-31 | -$30.30M 10-Q · filed 2022-11-08 | -$52.93M derived: sum of 2 quarters · filed 2022-11-08 | -$70.84M derived: sum of 3 quarters · filed 2022-11-08 | -$85.41M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2020-12-31 | -$22.63M 10-K · filed 2021-03-25 | -$40.54M derived: sum of 2 quarters · filed 2021-11-08 | -$55.11M derived: sum of 3 quarters · filed 2021-11-08 | -$67.25M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$17.91M 10-Q · filed 2021-11-08 | -$32.48M derived: sum of 2 quarters · filed 2021-11-08 | -$44.63M 10-Q · filed 2021-11-08 | -$54.50M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | -$14.57M 10-Q · filed 2021-11-08 | -$26.72M 10-Q · filed 2021-08-12 | -$36.59M derived: sum of 3 quarters · filed 2021-11-08 | -$45.86M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-03-31 | -$12.14M 10-Q · filed 2021-11-08 | -$22.02M derived: sum of 2 quarters · filed 2021-11-08 | -$31.29M derived: sum of 3 quarters · filed 2021-11-08 | -$43.58M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2019-12-31 | -$9.88M 10-K · filed 2021-03-25 | -$19.14M derived: sum of 2 quarters · filed 2021-03-25 | -$31.43M derived: sum of 3 quarters · filed 2021-03-25 | -$35.26M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$9.27M 10-K · filed 2021-03-25 | -$21.55M derived: sum of 2 quarters · filed 2021-03-25 | -$25.38M 10-Q · filed 2020-11-10 | -$28.45M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-06-30 | -$12.29M 10-K · filed 2021-03-25 | -$16.11M 10-Q · filed 2020-08-11 | -$19.18M derived: sum of 3 quarters · filed 2021-03-25 | -$21.54M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-03-31 | -$3.83M 10-K · filed 2021-03-25 | -$6.89M derived: sum of 2 quarters · filed 2021-03-25 | -$9.25M derived: sum of 3 quarters · filed 2021-03-25 | -$11.17M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2018-12-31 | -$3.07M 10-K · filed 2020-03-24 | -$5.43M derived: sum of 2 quarters · filed 2020-03-24 | -$7.34M derived: sum of 3 quarters · filed 2020-03-24 | -$8.93M 10-K · filed 2020-03-24 | |
| 2018-09-30 | -$2.36M 10-K · filed 2020-03-24 | -$4.27M derived: sum of 2 quarters · filed 2020-03-24 | -$5.87M derived: sum of 3 quarters · filed 2020-03-24 | ||
| 2018-06-30 | -$1.91M 10-K · filed 2020-03-24 | -$3.50M derived: sum of 2 quarters · filed 2020-03-24 | |||
| 2018-03-31 | -$1.59M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |